Company Profile & Origins
Takeda Pharmaceutical Company Limited is one of the world’s oldest and most respected pharmaceutical institutions, founded in 1781 in Osaka, Japan by Chobei Takeda I. From its beginnings as a family-run merchant business dealing in traditional Japanese and Chinese medicines, Takeda has grown into a global biopharmaceutical leader operating in over 80 countries. Its global headquarters are in Tokyo, Japan, and a regional office in Singapore for Asia-Pacific operations.
For more than two centuries, Takeda’s mission has remained rooted in its founding philosophy of integrity, fairness, honesty, and perseverance values that continue to guide its commitment to advancing health through science and innovation.
Today, Takeda focuses on vaccines, rare diseases, gastroenterology, oncology, and plasma-derived therapies, serving patients around the world with modern, evidence-based medical solutions.
Research, Innovation & Technology
Takeda’s Vaccines Business Unit (VBU) is dedicated to developing next-generation vaccines that address both long-standing and emerging infectious diseases, particularly those affecting tropical and underserved regions.
By combining traditional vaccine science with advanced biotechnological platforms, Takeda creates safe, scalable, and accessible immunization solutions.
Key strengths and technologies include:
- Recombinant protein and cell-culture-based vaccine technologies, ensuring precision, purity, and strong immune responses.
- Stabilized cold-chain systems designed for tropical climates, improving vaccine delivery in challenging environments.
- Global vaccine R&D centers in Japan, the United States, and Europe focused on dengue, norovirus, COVID-19, and Zika.
- Collaborations with WHO, CEPI, and PATH to ensure equitable vaccine access and rapid response to global health emergencies.
Vaccine Portfolio
Takeda’s vaccine portfolio reflects its focus on diseases with high public health impact in Asia and developing regions, particularly vector-borne and enteric diseases.
Key Vaccines:
- Dengue Vaccine: Qdenga® (TAK-003) – A breakthrough tetravalent dengue vaccine designed to protect against all four dengue virus serotypes. It is approved in several regions including Europe, the UK, and select Asian countries, and is expected to play a crucial role once available in the Philippines.
- Japanese Encephalitis Vaccine: Encevac® – Inactivated vaccine for prevention of Japanese Encephalitis, especially in endemic Asian regions.
- COVID-19 and Norovirus Vaccine Candidates: Ongoing research projects in collaboration with public health organizations.
Takeda’s vaccine developments emphasize safety, stability, and accessibility, especially in tropical and developing regions where infectious diseases pose a persistent challenge.
Medical Breakthroughs & Global Impact
Takeda’s recent advances have placed it among the leaders in global vaccine innovation:
- Developed Qdenga®, the first next-generation dengue vaccine suitable for both seropositive and seronegative individuals, marking a major step in global dengue prevention.
- Continues long-term research on Japanese Encephalitis and Zika virus vaccines to strengthen regional disease control.
- Partnered with global health agencies to support equitable vaccine access and emergency stockpiles for outbreaks in Asia and Latin America.
- Invests in sustainable cold-chain systems to ensure delivery integrity even in remote, warm-climate regions ideal for countries like the Philippines.
Presence in the Philippines
Takeda Healthcare Philippines, Inc. was established in 2014 and is headquartered in Bonifacio Global City, Taguig. Since then, the company has built a strong presence in both the pharmaceutical and vaccines sectors, collaborating closely with local health authorities, hospitals, and private organizations.
While Qdenga® is not yet commercially available in the Philippines as of 2025, Takeda’s presence highlights its commitment to bringing advanced vaccine solutions to Southeast Asia. The Philippine team actively engages in medical education, disease awareness, and public health partnerships, with a strong focused on preventive care.
Shared Commitment to Prevention
Through its partnership with Takeda, Affinity Vaccines aligns with a company that embodies scientific excellence and humanitarian purpose. Takeda’s focus on diseases that matter most to tropical countries reflects a shared commitment to innovation, access, and preventive health for all.
Protect your workforce and their families with scientifically proven vaccines from the world’s leading pharmaceutical partners.
Contact info@affinityvaccines.com to start your corporate immunization program with Affinity Vaccines today.
📩 Request for a Corporate Vaccination Proposal